'It will give me time': Pancreatic cancer patient approved for promising treatment

HonorHealth offers new drug that doubles pancreatic cancer survival

Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation to offer a new drug, Daraxonrasib, that based on early data nearly doubles the average survival time of patients with pancreatic cancer.

'It will give me time': Pancreatic cancer patient approved for promising treatment

'The idea of waiting is not ok': A Port St. Lucie pancreatic cancer patient was just approved for an experimental drug after a 62-day wait